Sartorius Stedim Biotech releases H1 2026 IR factsheet presentation

• Sartorius Stedim Biotech published its IR Factsheet for H1 2026.
• H1 sales revenue EUR 1.53 billion; up 6.4% year on year, or 8% at constant FX.
• Underlying EBITDA EUR 478.9 million; margin 31.4% versus 31% a year earlier.
• Underlying net profit after non-controlling interest EUR 235 million; underlying EPS EUR 2.42.
• Guidance: FY 2026 constant-currency revenue growth ~6% to ~10%; underlying EBITDA margin slightly above 31%; net debt/EBITDA slightly above 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.